Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00396331 · FLOW

Participant flow

AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts · Source last updated 2014-03-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Participants were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 7 aphereses or until ≥ 2\*10\^6 CD34+ cells/kg were collected.
    id
    FG000
    title
    G-CSF Plus Plerixafor
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        8
      type
      Failed to mobilize - no transplant
    2. reasons
      1. group Id
        FG000
        num Subjects
        5
      type
      Did not go on to transplant
    3. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Lost to Follow-up
    4. reasons
      1. group Id
        FG000
        num Subjects
        16
      type
      Death
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        100
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        100
      type
      Number of Participants Treated
    3. achievements
      1. comment
        7 participants had two transplants
        group Id
        FG000
        num Subjects
        87
      type
      Number of Participants Transplanted
    4. achievements
      1. group Id
        FG000
        num Subjects
        68
      type
      COMPLETED
    5. achievements
      1. group Id
        FG000
        num Subjects
        32
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
Four participants were enrolled in the study but never received plerixafor treatment so are not included below. Reasons for not receiving plerixafor included disease progression (2), infection (1) and insurance issues (1).
Complete source fields
groups
  1. description
    Participants were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 7 aphereses or until ≥ 2\*10\^6 CD34+ cells/kg were collected.
    id
    FG000
    title
    G-CSF Plus Plerixafor
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        8
      type
      Failed to mobilize - no transplant
    2. reasons
      1. group Id
        FG000
        num Subjects
        5
      type
      Did not go on to transplant
    3. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Lost to Follow-up
    4. reasons
      1. group Id
        FG000
        num Subjects
        16
      type
      Death
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        100
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        100
      type
      Number of Participants Treated
    3. achievements
      1. comment
        7 participants had two transplants
        group Id
        FG000
        num Subjects
        87
      type
      Number of Participants Transplanted
    4. achievements
      1. group Id
        FG000
        num Subjects
        68
      type
      COMPLETED
    5. achievements
      1. group Id
        FG000
        num Subjects
        32
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
Four participants were enrolled in the study but never received plerixafor treatment so are not included below. Reasons for not receiving plerixafor included disease progression (2), infection (1) and insurance issues (1).

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice